Top

Published in:

01-08-2018 | Original Article

Assessment of tumor response to chemoradiotherapy and predicting prognosis in patients with head and neck squamous cell carcinoma by PERCIST

Authors: Takayuki Katsuura, Kazuhiro Kitajima, Masayuki Fujiwara, Tomonori Terada, Nobuhiro Uwa, Kazuma Noguchi, Hiroshi Doi, Yukihisa Tamaki, Rika Yoshida, Tatsuya Tsuchitani, Masahiro Fujita, Koichiro Yamakado

Published in: Annals of Nuclear Medicine | Issue 7/2018

Abstract

Purpose

To evaluate therapeutic response to chemoradiotherapy and prediction of recurrence and death in patients with head and neck squamous cell carcinoma (HNSCC) using Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST).

Materials and methods

Forty-two patients (mean 63.4, range 20–79 years) with nasopharyngeal (n = 10), oropharyngeal (n = 13), hypopharyngeal (n = 11), or laryngeal (n = 8) cancer underwent fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) before and approximately 3 months (mean 95.0, range 70–119 days) after undergoing concurrent chemoradiotherapy. The effect of PERCIST regarding progression-free survival (PFS) and overall survival (OS) was examined using log-rank and Cox methods.

Results

Complete metabolic response (CMR), partial metabolic response (PMR), stable metabolic disease (SMD), and progressive metabolic disease shown by PERCIST were seen in 30 (71.4%), 9 (21.4%), 3 (7.1%), and 0 patients, respectively. Fourteen (33.3%) developed recurrent disease (median follow-up 27.2, range 8.7–123.1 months) and 9 (21.4%) died (median follow-up 43.6, range 9.6–132.6 months). Furthermore, 4 (13.3%) of 30 patients with CMR developed recurrence, while 7 (77.8%) of 9 with PMR and all 3 (100%) with SMD developed recurrence. Two (6.7%) of 30 patients with CMR, 4 (44.4%) of 9 with PMR, and all 3 (100%) with SMD died. Patients who achieved CMR showed significantly longer PFS and OS as compared to those who did not (PMR and SMD) (both, p < 0.0001).

Conclusion

PERCIST is useful for evaluating therapeutic response to chemoradiotherapy and predicting recurrence and death in HNSCC patients.

Ferlito A, Corry J, Silver CE, Shaha AR, Thomas Robbins K, Rinaldo A. Planned neck dissection for patients with complete response to chemoradiotherapy: a concept approaching obsolescence. Head Neck. 2010;32:253–61.PubMed

Esteller E, Vega MC, Lopez M, Quer M, León X. Salvage surgery after locoregional failure in head and neck carcinoma patients treated with chemoradiotherapy. Eur Arch Otorhinolaryngol. 2011;268:295–301.CrossRefPubMed

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228 – 47.CrossRefPubMed

Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S-50S.PubMed

Odawara S, Kitajima K, Katsuura T, Kurahashi Y, Shinohara H, Yamakado K. Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT—RECIST 1.1 vs. PERCIST 1.0. Eur J Radiol. 2018;101:65–71.CrossRefPubMed

Kitajima K, Nakatani K, Yamaguchi K, Nakajo M, Tani A, Ishibashi M, et al. Response to neoadjuvant chemotherapy for breast cancer judged by PERCIST—multicenter study in Japan. Eur J Nucl Med Mol Imaging. 2018. https://doi.org/10.1007/s00259-018-4008-1.PubMedCrossRef

Isles MG, McConkey C, Mehanna HM. A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol. 2008;33:210–22.CrossRefPubMed

Gupta T, Master Z, Kannan S, Agarwal JP, Ghsoh-Laskar S, Rangarajan V, et al. Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011;38:2083–95.CrossRefPubMed

Kapoor V, Fukui MB, McCook BM. Role of ¹⁸FFDG PET/CT in the treatment of head and neck cancers: posttherapy evaluation and pitfalls. AJR Am J Roentgenol. 2005;184:589–97.CrossRefPubMed

10.

Passero VA, Branstetter BF, Shuai Y, Heron DE, Gibson MK, Lai SY, et al. Response assessment by combined PET-CT scan versus CT scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy. Ann Oncol. 2010;21:2278–83.CrossRefPubMed

11.

Matoba M, Tuji H, Shimode Y, Kondo T, Oota K, Tonami H. Lesion regression rate based on RECIST: prediction of treatment outcome in patients with head and neck cancer treated with chemoradiotherapy compared with FDG PET-CT. J Radiat Res. 2015;56:553 – 60.CrossRefPubMedPubMedCentral

12.

Bird T, Barrington S, Thavaraj S, Jeannon JP, Lyons A, Oakley R, et al. ¹⁸F-FDG PET/CT to assess response and guide ris-stratified follow-up after chemoradiotherapy for oropharyngeal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2016;43:1239–47.CrossRefPubMed

13.

Skougaard K, Nielsen D, Jensen BV, Hendel HW. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab. J Nucl Med. 2013;54:1026–31.CrossRefPubMed

14.

Minamimoto R, Fayad L, Advani R, Vose J, Macapinlac H, Meza J, et al. Diffuse large B-cell lymphoma: Prospective multicenter comparison of early interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST criteria for early therapeutic monitoring. Radiology. 2016;280:220–9.CrossRefPubMedPubMedCentral

15.

Cho SY, Lipson EJ, Im HJ, Rowe SP, Gonzalez EM, Blackford A, et al. Prediction of Response to immune checkpoint inhibitor therapy using early-time-point ¹⁸F-FDG PET/CT imaging in patients with advanced melanoma. J Nucl Med. 2017;58:1421–8.CrossRefPubMedPubMedCentral

16.

Fledelius J, Winther-Larsen A, Khalil AA, Bylov CM, Hjorthaug K, Bertelsen A, et al. ¹⁸F-FDG PET/CT for vry erly rsponse ealuation pedicts CT rsponse in elotinib-teated non-small cell lung cancer patients: a comparison of assessment methods. J Nucl Med. 2017;58:1931–7.CrossRefPubMed

Title: Assessment of tumor response to chemoradiotherapy and predicting prognosis in patients with head and neck squamous cell carcinoma by PERCIST
Authors: Takayuki Katsuura
Kazuhiro Kitajima
Masayuki Fujiwara
Tomonori Terada
Nobuhiro Uwa
Kazuma Noguchi
Hiroshi Doi
Yukihisa Tamaki
Rika Yoshida
Tatsuya Tsuchitani
Masahiro Fujita
Koichiro Yamakado
Publication date: 01-08-2018
Publisher: Springer Japan
Published in: Annals of Nuclear Medicine / Issue 7/2018
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-018-1267-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Assessment of tumor response to chemoradiotherapy and predicting prognosis in patients with head and neck squamous cell carcinoma by PERCIST

Abstract

Purpose

Materials and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2018

Optimal monochromatic color combinations for fusion imaging of FDG-PET and diffusion-weighted MR images

Is 18F-FDG PET/CT useful for the differential diagnosis of solitary pulmonary nodules in patients with idiopathic pulmonary fibrosis?

Effects of rs591323 on serotonin transporter availability in healthy male subjects

Clinical application of 99mTc-HYNIC-TOC SPECT/CT in diagnosing and monitoring of pancreatic neuroendocrine neoplasms

Reliable radiosynthesis of 4-[10B]borono-2-[18F]fluoro-l-phenylalanine with quality assurance for boron neutron capture therapy-oriented diagnosis

Radiation exposure after 177Lu-DOTATATE and 177Lu-PSMA-617 therapy